Navigation Links
MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
Date:9/10/2009

Monday, September 14, 2009 at 7:15 a.m. ET to review the data presented at the 14th Congress of the International Headache Society. The webcast will be accessible in the Investor Relations section of the company's website at www.mappharma.com.

About LEVADEX(TM)

LEVADEX orally inhaled migraine therapy is a novel migraine therapy candidate in Phase 3 development. Patients administer LEVADEX themselves using the company's proprietary TEMPO(R) inhaler. LEVADEX is designed to be differentiated from existing migraine treatments. It is a novel formulation of dihydroergotamine (DHE), a drug used intravenously in clinical settings to effectively and safely treat migraines. Based on clinical results, the company believes that LEVADEX has the potential to provide both fast onset of action and sustained pain relief and other migraine symptom relief in an easy-to-use and non-invasive at-home therapy.

LEVADEX is designed to incorporate the multiple beneficial mechanisms of action that allow DHE to block initiation of migraine, limit pain, reduce inflammation and stop a migraine at any point in the migraine cycle. Based on research to date, including the FREEDOM-301 trial, which was the first Phase 3 trial of LEVADEX, the company believes the unique pharmacokinetic profile of LEVADEX has the potential to effectively treat migraine, while minimizing the side effects commonly seen with DHE and other currently available medicines.

About Migraine

Migraine is a common, debilitating neurological disorder that affects approximately 30 million people in the United States, according to the National Headache Foundation. Limitations of oral triptans, the class of prescription drugs widely used for migraines, include slow onset of significant pain relief between 45 and 90 minutes, substantial variability in patient re
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... 17, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... has filed a preliminary prospectus supplement to its effective shelf ... similar filing with securities regulatory authorities in each of the ... a public offering of its common shares to raise gross ... Company will also grant to the underwriters of the Offering ...
(Date:6/17/2013)... , June 17, 2013 Prime Therapeutics, in collaboration ... agency, Larsen, was awarded the Silver Anvil for its internal ... The award was presented at the Public Relations Society of ... June 13 at the AXA Equitable Center in ... Silver Anvil, which has been presented annually since 1946, is ...
(Date:6/17/2013)... N.J. , June 17, 2013 /PRNewswire-iReach/ -- ... the company,s new X-4S pressure sensitive labeling head. ... stringent speed and performance requirements that serialization demands. ... in, WLS is uniquely qualified to work with ... in their serialization and track and trace implementation ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4Prime Therapeutics receives prestigious Silver Anvil Award from Public Relations Society of America 2Weiler Labeling Introduces Serialization-Capable X-4S Labeling Head 2
... SAN DIEGO, Oct. 26 Horizon Therapeutics, Inc., ... analysis from two pivotal Phase 3 trials (REDUCE-1 ... a combination of ibuprofen with high-dose famotidine. ... factors for the development of non-steroidal anti-inflammatory drug ...
... Executives for Medco Health Solutions, Inc. (NYSE: ... investor conferences: , Timothy Wentworth, Medco,s group president for ... Conference on Wednesday, November 4, 2009 at 2:10 p.m. ... David B. Snow Jr., Medco chairman and CEO, will ...
Cached Medicine Technology:Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 2Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 3Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 4Medco to Present at November 2009 Investor Conferences 2
(Date:6/18/2013)... (PRWEB) June 18, 2013 Biomet ... continue to move forward in a multidistrict litigation in ... LLP reports. According to court records, the litigation’s ... at which time the Court also convened a motions ... issues pertinent to the Biomet hip replacement litigation. ...
(Date:6/18/2013)... Seven-year-old Riley Salz of Encino, California, is ... 40 hours a week of applied behavior analysis (ABA) ... for Autism and Related Disorders (CARD). Riley has been ... experienced remarkable progress, including learning to speak, starting conversations, ... journey through autism is now featured in CARD’s “Mission ...
(Date:6/18/2013)... Recent research has shown that cancer cells have a ... normal cells. Now, scientists at The University of Texas ... provide a new strategy to combat lung cancer. , ... journal PLOS ONE , UT Dallas researchers compared ... normal lung cells taken from the same patient. ...
(Date:6/18/2013)... at Case Western Reserve University,s College of Arts ... made available avatarsvirtual patientsto train speech-language pathologists. ... to evaluate speech-language disorders to practice using an ... because a diagnosis doesn,t have to be made ... studying to become speech-language pathologists have previously relied ...
(Date:6/18/2013)... Belleville, Ill. (PRWEB) June 18, 2013 More ... older are living with HIV/AIDS, according to the Centers for ... don’t know they are infected. In support of National HIV ... Social Security Disability Insurance (SSDI) representation, the CDC ... HIV testing. , The CDC reports about 50,000 new ...
Breaking Medicine News(10 mins):Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:UT Dallas study suggests new approach to fight lung cancer 2Health News:UT Dallas study suggests new approach to fight lung cancer 3Health News:SimuCase avatars advance speech-language pathology training 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3
... boosted hearing in such children , THURSDAY, Feb. ... hearing improvement for children and teens with single-sided deafness, ... 3 percent of children have deafness on one side, ... difficulties and behavioral problems. Traditional external hearing aids are ...
... ... NFL Draft pick would have to find a personal trainer, physical therapist, ... them compete with the best athletes in the world. But Athletes, ... offered an NFL Combine preparation program, and this year Trigger Point Performance ...
... , Scientists at the Johns Hopkins Kimmel Cancer Center ... cancer patients to develop individualized blood tests they believe ... blood tests, believed to be the first of their ... therapy and determine cancer recurrence., "We believe this ...
... It is not unusual to hear people blame their metabolism ... process that shapes how our bodies turn food into energy -- ... fit into your favorite jeans. In fact, differences in ... cells, though the mechanism behind it is unclear. Now new research ...
... patients perform significantly better on tests of cognitive function than ... MRI scans of the patients showed that the fitter MS ... show deterioration as a result of MS, as well as ... that aerobic fitness has a protective effect on parts of ...
... ... Opinion Survey and Special Supplement on Health Care Reform , ... Indianapolis, IN (Vocus) February 18, 2010 -- ... benefits advisory organizations, today announced the opening of the 2010 UBA Employer Opinion ...
Cached Medicine News:Health News:Small Time Company Rolls into the Big League: Trigger Point Performance Therapy Selected to Attend Athletes' Performance NFL Combine Preparation Program 2Health News:Small Time Company Rolls into the Big League: Trigger Point Performance Therapy Selected to Attend Athletes' Performance NFL Combine Preparation Program 3Health News:Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing 2Health News:Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing 3Health News:Chemical tags likely to affect metabolism, cancer development 2Health News:Exercise helps protect brain of multiple sclerosis patients 2Health News:Exercise helps protect brain of multiple sclerosis patients 3Health News:Employers Voice Opinions on Health Care Plans, Gain Insights on Health Care Reform 2Health News:Employers Voice Opinions on Health Care Plans, Gain Insights on Health Care Reform 3
Iron / TIBC (Ferrozine). Storage temp: 2 - 8 C. Linearity: 0 - 500 ug/dl. Expected values: from TIBC 250 - 400 ug/dl, from Iron 40 - 160 ug/dl. Available with Calibrator and Number of test are 100....
For the quantitative determination of iron, total iron-binding capacity in human serum....
HDL Cholesterol, liquid....
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
Medicine Products: